| Name | Bcl xL |
|---|---|
| Synonyms | Apoptosis regulator Bcl X; BCL XL/S; BCL2 like 1; BCL2 related gene; BCL2 like 1 isoform 1; BCL2L; BCL2L1; BCLX… |
| Name | biphenyl |
|---|---|
| CAS | 1,1′-biphenyl |
| PubMed | Abstract | RScore(About this table) | |
|---|---|---|---|
| 19684859 | Keuling AM, Felton KE, Parker AA, Akbari M, Andrew SE, Tron VA: RNA silencing of Mcl-1 enhances ABT-737-mediated apoptosis in melanoma: role for a caspase-8-dependent pathway. PLoS One. 2009 Aug 17;4(8):e6651. ABT-737, a small-molecule inhibitor of Bcl-2, Bcl-xl and Bcl-w, has demonstrated efficacy in several forms of leukemia, lymphoma as well as solid tumors. |
1(0,0,0,1) | Details |
| 20038611 | High LM, Szymanska B, Wilczynska-Kalak U, Barber N, O'Brien R, Khaw SL, Vikstrom IB, Roberts AW, Lock RB: The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs. Mol Pharmacol. 2010 Mar;77(3):483-94. Epub 2009 Dec 28. ABT-737, a Bcl-2 homology domain 3 mimetic (for structure, see Nature 435:677-681, 2005) inhibits the prosurvival function of Bcl-2, Bcl-X (L), and Bcl-w. |
1(0,0,0,1) | Details |
| 18807035 | Begley J, Vo DD, Morris LF, Bruhn KW, Prins RM, Mok S, Koya RC, Garban HJ, Comin-Anduix B, Craft N, Ribas A: Immunosensitization with a Bcl-2 small molecule inhibitor. . Cancer Immunol Immunother. 2009 May;58(5):699-708. Epub 2008 Sep 20. ABT-737, a small molecule inhibitor of the antiapoptotic proteins Bcl-2, Bcl-w and Bcl-x (L), was tested for the ability to increase antitumor immune responses in two tumor immunotherapy animal models. |
1(0,0,0,1) | Details |
| 19380879 | Gallenne T, Gautier F, Oliver L, Hervouet E, Noel B, Hickman JA, Geneste O, Cartron PF, Vallette FM, Manon S, Juin P: Bax activation by the BH3-only protein Puma promotes cell dependence on antiapoptotic Bcl-2 family members. J Cell Biol. 2009 Apr 20;185(2):279-90. Finally, endogenous Puma is involved in the apoptotic response of human colorectal cancer cells to the Bcl-2/Bcl-xL inhibitor ABT-737, even in conditions where the expression of Mcl-1 is down-regulated. |
1(0,0,0,1) | Details |
| 18591385 | Paoluzzi L, Gonen M, Bhagat G, Furman RR, Gardner JR, Scotto L, Gueorguiev VD, Heaney ML, Manova K, O'Connor OA: The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies. Blood. 2008 Oct 1;112(7):2906-16. Epub 2008 Jun 30. ABT-737 is a BH3-only mimetic and potent inhibitor of the antiapoptotic Bcl-2 family members Bcl-2, Bcl-X (L), and Bcl-w. |
1(0,0,0,1) | Details |
| 19494271 | Bardwell PD, Gu J, McCarthy D, Wallace C, Bryant S, Goess C, Mathieu S, Grinnell C, Erickson J, Rosenberg SH, Schwartz AJ, Hugunin M, Tarcsa E, Elmore SW, McRae B, Murtaza A, Wang LC, Ghayur T: The Bcl-2 family antagonist ABT-737 significantly inhibits multiple animal models of autoimmunity. J Immunol. 2009 Jun 15;182(12):7482-9. ABT-737, which was originally developed for oncology, is a potent inhibitor of Bcl-2, Bcl-x (L), and Bcl-w protein function. |
1(0,0,0,1) | Details |
| 19229860 | Lee DH, Szczepanski MJ, Lee YJ: Magnolol induces apoptosis via inhibiting the EGFR/PI3K/Akt signaling pathway in human prostate cancer cells. J Cell Biochem. 2009 Apr 15;106(6):1113-22. Protein interaction assay revealed that Bcl-xL, an anti-apoptotic protein, was associated with Bad during treatment with magnolol. |
1(0,0,0,1) | Details |
| 18362892 | Tajeddine N, Galluzzi L, Kepp O, Hangen E, Morselli E, Senovilla L, Araujo N, Pinna G, Larochette N, Zamzami N, Modjtahedi N, Harel-Bellan A, Kroemer G: Hierarchical involvement of Bak, VDAC1 and Bax in cisplatin-induced cell death. Oncogene. 2008 Jul 10;27(30):4221-32. Epub 2008 Mar 24. In VDAC1-depleted cells, the failure of CDDP to activate Bax could be reversed by means of the Bcl-2/Bcl-X (L) antagonist ABT-737, which concomitantly restored CDDP cytotoxicity. |
1(0,0,0,1) | Details |
| 18160428 | Hickman JA, Hardwick JM, Kaczmarek LK, Jonas EA: Bcl-xL inhibitor ABT-737 reveals a dual role for Bcl-xL in synaptic transmission. J Neurophysiol. 2008 Mar;99(3):1515-22. Epub 2007 Dec 26. |
1(0,0,0,1) | Details |
| 19726085 | Cencic R, Carrier M, Trnkus A, Porco JA Jr, Minden M, Pelletier J: Synergistic effect of inhibiting translation initiation in combination with cytotoxic agents in acute myelogenous leukemia cells. Leuk Res. 2010 Apr;34(4):535-41. Epub 2009 Sep 1. Silvestrol shows synergy with standard-of-care agents in AML cell lines and synergizes with ABT-737, a small molecule inhibitor of Bcl-X (L) and Bcl-2. |
1(0,0,0,1) | Details |
| 18987671 | Miller LA, Goldstein NB, Johannes WU, Walton CH, Fujita M, Norris DA, Shellman YG: BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis. J Invest Dermatol. 2009 Apr;129(4):964-71. Epub 2008 Nov 6. The BH3 mimetic ABT-737 is a potent small molecule inhibitor of the anti-apoptotic proteins Bcl-2/Bcl-X (L)/Bcl-w. |
1(0,0,0,1) | Details |
| 18819468 | Tang Y, Zhang DY, Wu XM: [Progress in small-molecule inhibitors of Bcl-2 family proteins] . Yao Xue Xue Bao. 2008 Jul;43(7):669-77. High expression of anti-apoptotic members such as Bcl-2 and Bcl-xL are commonly found in human cancers. |
1(0,0,0,1) | Details |
| 19759519 | Iwasawa M, Miyazaki T, Nagase Y, Akiyama T, Kadono Y, Nakamura M, Oshima Y, Yasui T, Matsumoto T, Nakamura T, Kato S, Hennighausen L, Nakamura K, Tanaka S: The antiapoptotic protein Bcl-xL negatively regulates the bone-resorbing activity of osteoclasts in mice. J Clin Invest. 2009 Oct;119(10):3149-59. doi: 10.1172/JCI39819. Epub 2009 Sep 14. |
7(0,0,0,7) | Details |
| 19839062 | Hikita H, Takehara T, Kodama T, Shimizu S, Hosui A, Miyagi T, Tatsumi T, Ishida H, Ohkawa K, Li W, Kanto T, Hiramatsu N, Hennighausen L, Yin XM, Hayashi N: BH3-only protein bid participates in the Bcl-2 network in healthy liver cells. Hepatology. 2009 Dec;50(6):1972-80. Hepatocyte-specific knockout (KO) of Bcl-xL leads to naturally-occurring apoptosis despite co-expression of Mcl-1, which shares a similar anti-apoptotic function. |
5(0,0,0,5) | Details |
| 19805519 | Chen S, Dai Y, Pei XY, Grant S: Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1. Mol Cell Biol. 2009 Dec;29(23):6149-69. Epub 2009 Oct 5. |
4(0,0,0,4) | Details |
| 19246337 | Li R, Zang Y, Li C, Patel NS, Grandis JR, Johnson DE: ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway. Mol Pharmacol. 2009 May;75(5):1231-9. Epub 2009 Feb 25. Overexpression of Bcl-X (L), an antiapoptotic Bcl-2 family member, occurs in a majority of head and neck squamous cell carcinomas (HNSCCs) and correlates with chemotherapy resistance in this disease. |
3(0,0,0,3) | Details |
| 19060244 | Zeuner A, Pedini F, Francescangeli F, Signore M, Girelli G, Tafuri A, De Maria R: Activity of the BH3 mimetic ABT-737 on polycythemia vera erythroid precursor cells. Blood. 2009 Feb 12;113(7):1522-5. Epub 2008 Dec 5. We found that erythroid precurors derived from patients with polycythemia vera (PV) with medium and high JAK2V617F mutation rates often express elevated levels of the antiapoptotic molecules Bcl-2 and Bcl-X (L) (5 of 12 patients with 3 to 7 times Bcl-2 and 3 of 12 patients with 4 to 7 times Bcl-X (L) than average normal controls) and are more resistant to myelosuppressive drugs than normal erythroblasts. |
3(0,0,0,3) | Details |
| 19060243 | Whitecross KF, Alsop AE, Cluse LA, Wiegmans A, Banks KM, Coomans C, Peart MJ, Newbold A, Lindemann RK, Johnstone RW: Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors. Blood. 2009 Feb 26;113(9):1982-91. Epub 2008 Dec 5. The apoptotic and therapeutic activities of the histone deacetylase inhibitor (HDACi) vorinostat are blocked by overexpression of Bcl-2 or Bcl-X (L). |
3(0,0,0,3) | Details |
| 20020680 | Goreshnik I, Maly DJ: A small molecule-regulated guanine nucleotide exchange factor. . J Am Chem Soc. 2010 Jan 27;132(3):938-40. This approach uses the interaction of the antiapoptotic protein Bcl-xL and a BH3 peptide as an autoinhibitory switch that can be controlled with a small molecule. |
2(0,0,0,2) | Details |
| 19088028 | Okumura K, Huang S, Sinicrope FA: Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737. Clin Cancer Res. 2008 Dec 15;14(24):8132-42. |
2(0,0,0,2) | Details |
| 18413764 | Huang S, Sinicrope FA: BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells. Cancer Res. 2008 Apr 15;68(8):2944-51. ABT-737 disrupted the interaction of Bak with Bcl-x (L) in both cell lines. |
2(0,0,0,2) | Details |
| 18806758 | Vogler M, Dinsdale D, Dyer MJ, Cohen GM: Bcl-2 inhibitors: small molecules with a big impact on cancer therapy. Cell Death Differ. 2009 Mar;16(3):360-7. Epub 2008 Sep 19. Antiapoptotic Bcl-2 family members may be divided into two subclasses, one comprising Bcl-2, Bcl-X (L) and Bcl-w and the other Mcl-1 and Bcl2A1. |
2(0,0,0,2) | Details |
| 19228717 | Kang MH, Reynolds CP: Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res. 2009 Feb 15;15(4):1126-32. One pathway being targeted for antineoplastic therapy is the anti-apoptotic B-cell lymphoma-2 (Bcl-2) family of proteins (Bcl-2, Bcl-XL, Bcl-w, Mcl-1, Bfl1/A-1, and Bcl-B) that bind to and inactivate BH3-domain pro-apoptotic proteins. |
2(0,0,0,2) | Details |
| 18507762 | Deng J, Qian Y, Geng L, Chen J, Wang X, Xie H, Yan S, Jiang G, Zhou L, Zheng S: Involvement of p38 mitogen-activated protein kinase pathway in honokiol-induced apoptosis in a human hepatoma cell line (hepG2). Liver Int. 2008 Dec;28(10):1458-64. Epub 2008 May 26. Western blots were used to analyse the expression of various proteins (procaspase-9, procaspase-3, cleaved caspase-3, cytochrome c, Bcl-2, Bax, Bad, Bcl-X (L) and p38). |
2(0,0,0,2) | Details |
| 19726685 | Lee EF, Czabotar PE, Yang H, Sleebs BE, Lessene G, Colman PM, Smith BJ, Fairlie WD: Conformational changes in Bcl-2 pro-survival proteins determine their capacity to bind ligands. J Biol Chem. 2009 Oct 30;284(44):30508-17. Epub 2009 Sep 2. Here we describe new structures of mutant BH3 peptides bound to Bcl-x (L) and Mcl-1. |
2(0,0,0,2) | Details |
| 18056200 | Witham J, Valenti MR, De-Haven-Brandon AK, Vidot S, Eccles SA, Kaye SB, Richardson A: The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin. Clin Cancer Res. 2007 Dec 1;13(23):7191-8. |
2(0,0,0,2) | Details |
| 18641058 | Jin YC, Kim KJ, Kim YM, Ha YM, Kim HJ, Yun UJ, Bae KH, Kim YS, Kang SS, Seo HG, Lee JH, Chang KC: Anti-apoptotic effect of magnolol in myocardial ischemia and reperfusion injury requires extracellular signal-regulated kinase1/2 pathways in rat in vivo. Exp Biol Med. 2008 Oct;233(10):1280-8. Epub 2008 Jul 18. Apoptosis related events such as p-ERK, p-Bad, Bcl-xl and cytochrome c expression were evaluated by Western blot analysis and myocardial caspase-3 activity was also measured. |
2(0,0,0,2) | Details |
| 18281560 | Hahm ER, Arlotti JA, Marynowski SW, Singh SV: Honokiol, a constituent of oriental medicinal herb magnolia officinalis, inhibits growth of PC-3 xenografts in vivo in association with apoptosis induction. Clin Cancer Res. 2008 Feb 15;14(4):1248-57. Honokiol-induced apoptosis correlated with induction of Bax, Bak, and Bad and a decrease in Bcl-xL and Mcl-1 protein levels. |
2(0,0,0,2) | Details |
| 19557638 | Jayanthan A, Howard SC, Trippett T, Horton T, Whitlock JA, Daisley L, Lewis V, Narendran A: Targeting the Bcl-2 family of proteins in Hodgkin lymphoma: in vitro cytotoxicity, target modulation and drug combination studies of the Bcl-2 homology 3 mimetic ABT-737. Leuk Lymphoma. 2009 Jul;50(7):1174-82. Anti-apoptotic proteins such as Bcl-2 and Bcl-x have been associated with the growth and survival of Hodgkin Reed-Sternberg cells and are potential therapeutic targets. |
2(0,0,0,2) | Details |
| 18949058 | Cragg MS, Jansen ES, Cook M, Harris C, Strasser A, Scott CL: Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. J Clin Invest. 2008 Nov;118(11):3651-9. Epub 2008 Oct 23. This treatment was successful because of both efficient antagonism of the prosurvival Bcl-2 family member Mcl-1 by Bim and inhibition of Bcl-2 and Bcl-x (L) by ABT-737. |
1(0,0,0,1) | Details |
| 19074726 | Chen J, Fiskus W, Eaton K, Fernandez P, Wang Y, Rao R, Lee P, Joshi R, Yang Y, Kolhe R, Balusu R, Chappa P, Natarajan K, Jillella A, Atadja P, Bhalla KN: Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism. Blood. 2009 Apr 23;113(17):4038-48. Epub 2008 Dec 12. Cotreatment with the Bcl-2/Bcl-x (L) antagonist ABT-737 decreased resistance and synergistically induced apoptosis of human CTCL cells. |
1(0,0,0,1) | Details |
| 19641525 | Mason KD, Khaw SL, Rayeroux KC, Chew E, Lee EF, Fairlie WD, Grigg AP, Seymour JF, Szer J, Huang DC, Roberts AW: The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia. Leukemia. 2009 Nov;23(11):2034-41. Epub 2009 Jul 30. ABT-737 is a BH3 mimetic compound that selectively targets BCL2 and BCLX (L). |
1(0,0,0,1) | Details |
| 19366808 | Kurosu T, Ohki M, Wu N, Kagechika H, Miura O: Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway. Cancer Res. 2009 May 1;69(9):3927-36. Epub 2009 Apr 14. Sorafenib-induced apoptosis in these cells and Ph+ leukemic cells was synergistically enhanced by rottlerin, bortezomib, or ABT-737 and inhibited by the pan-caspase inhibitor BOC-d-fmk or the overexpression of Bcl-XL. |
1(0,0,0,1) | Details |
| 18689543 | Stolz C, Hess G, Hahnel PS, Grabellus F, Hoffarth S, Schmid KW, Schuler M: Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis. Blood. 2008 Oct 15;112(8):3312-21. Epub 2008 Aug 8. Expression of antiapoptotic Bcl-xL confers resistance against rituximab-induced apoptosis in vitro and rituximab treatment of xenografted B-NHL in vivo. |
1(0,0,0,1) | Details |
| 18767026 | Azmi AS, Mohammad RM: Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy. J Cell Physiol. 2009 Jan;218(1):13-21. Cancer cells that are resistant to various anti-cancer drugs and treatment regimen are found to over express these Bcl-2 proteins such as Bcl-2, Bcl-X (L), Mcl-1, Bcl-w, and A1/Bfl1. |
1(0,0,0,1) | Details |
| 19737541 | Ugarenko M, Nudelman A, Rephaeli A, Kimura K, Phillips DR, Cutts SM: ABT-737 overcomes Bcl-2 mediated resistance to doxorubicin-DNA adducts. Biochem Pharmacol. 2010 Feb 1;79(3):339-49. Epub 2009 Sep 6. The small molecule inhibitor, ABT-737, which binds to and inhibits Bcl-2, Bcl-xL and Bcl-w, was used in combination with doxorubicin/AN-9 treatments to overcome resistance to doxorubicin-DNA adducts in Bcl-2 overexpressing HL-60 cells (HL-60/Bcl-2). |
1(0,0,0,1) | Details |